GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ:GLGC) announced today that the Company’s shareholders have approved both the sale of its Genomics Assets to Ocimum Biosolutions and the renaming of the Company as Ore Pharmaceuticals Inc. The shareholder vote yesterday and completion of the sale of the Genomics Assets expected later this week will launch effectively Ore Pharmaceuticals as a new company focused on drug repositioning and development. After the filing of necessary legal documents later this week, the Company will be renamed Ore Pharmaceuticals Inc. The Company’s stock will continue to trade on the NASDAQ exchange and its stock ticker will change to ORXE. Ownership of the name Gene Logic will transfer to Ocimum on the date of closing of the sale agreement.
